Prime Medicine
Business Services · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
60 1st St, Cambridge, Massachusetts, 021...Phone Number
(617) 465-0013Website
www.primemedicine.comRevenue
<$5 MillionStock Symbol
PRMEIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
2
2
1
1
1
About Prime Medicine
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic therapies to address the spectrum of diseases by deploying gene editing technology in the United States. It offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor.Explore more
Prime Medicine Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Prime Medicine your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Prime Medicine, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Prime Medicine
Website visits: Recent activity has been detected on your website
Click to see if Prime Medicine had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Prime Medicine recently announced quarterly report
Product Launch: Get notified when Prime Medicine launches new products
Funding: Get notified immidiatlly once Prime Medicine has new funding data
Check if Prime Medicine has recently received funding, and reach out quickly before it becomes old news!
Check out if Prime Medicine is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Prime Medicine
Compare insights from companies similar to Prime Medicine, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Prime Medicine is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Prime Medicine is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Prime Medicine.
Prime Medicine financials insights
Gather financial insights about Prime Medicine, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series B
$200M
2022
Stock Offering
$175M
2025
Other Financing Round
$24M
Prime Medicine Tech Stack
A closer look at the technologies used by Prime Medicine
Most Recent Scoops
Open Position
Person-Based
Pharmaceuticals
Person-Based
Pharmaceuticals, Clinical Operations
Project
Prime Medicine is targeting an IND/CTA filing for its Alpha-1 Antitrypsin Deficiency (AAT) program in mid-2025, with initial clinical data expected in 2027.
Clinical Operations
Project
Medical Research, Pharmaceuticals, Clinical Operations
Prime Medicine News & Media
Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
-- RMAT designation granted based on Phase 1/2 clinical data, including results previously published in The New England Journal of Medicine, demonstrating PM359’s potential to address unmet need in p47phox-deficient CGD -- -- Designation enables early and intensive FDA engagement, and provides eligibility for rolling and priority Biologics License Application review --Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease
-- First clinical authorization for an in vivo Prime Editing therapy from Prime Medicine -- -- PM577a targets the H1069Q mutation in the ATP7B gene, the most prevalent WD-causing allele in North America and Europe --Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026?
Two biotech innovators, two very different risk profiles: one with commercial products and another betting on next-gen gene editing breakthroughs.Prime Medicine, Inc. (PRME) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript
Prime Medicine, Inc. (PRME) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 10, 2026 10:40 AM EDTCompany ParticipantsAllan Reine - CEO...
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding Prime Medicine
Sign Up For FreeTo access detailed company insights
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic therapies to address the spectrum of diseases by deploying gene editing technology in the United States. It offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stran... Read More
